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OBJECTIVEdAlthough low HDL cholesterol (HDL-C) is an established risk factor for athero-
sclerosis, data on HDL-C and the risk of microvascular disease are limited.We tested the association
between HDL-C and microvascular disease in a cohort of patients with type 2 diabetes.
RESEARCH DESIGN ANDMETHODSdA total of 11,140 patients with type 2 diabetes
and at least one additional vascular risk factor were followed a median of 5 years. Cox proportional
hazardsmodelswere used to assess the association between baselineHDL-C and the development of
new or worsening microvascular disease, deﬁned prospectively as a composite of renal and retinal
events.
RESULTSdThe mean baseline HDL-C level was 1.3 mmol/L (SD 0.45 mmol/L [range 0.1–4.0]).
During follow-up, 32% of patients developed new or worsening microvascular disease, with 28%
experiencing a renal event and 6% a retinal event. Comparedwith patients in the highest third, those
in the lowest third had a 17% higher risk of microvascular disease (adjusted hazard ratio 1.17
[95% CI 1.06–1.28], P = 0.001) after adjustment for potential confounders and regression di-
lution. This was driven by a 19%higher risk of renal events (1.19 [1.08–1.32], P = 0.0005). There
was no association between thirds of HDL-C and retinal events (1.01 [0.82–1.25], P = 0.9).
CONCLUSIONSdIn patients with type 2 diabetes, HDL-C level is an independent risk factor
for the development of microvascular disease affecting the kidney but not the retina.
Diabetes Care 35:2201–2206, 2012
Diabetes is the primary cause of end-stage kidney disease (1) and loss ofvision (2) in developed nations. Mi-
crovascular disease is a common compli-
cation of type 2 diabetes and develops
insidiously with few symptoms until irre-
versible damage has occurred. The two
principal and reversible risk factors for
the development and progression of ne-
phropathy and retinopathy are blood glu-
cose and blood pressure levels (1,2).
However, despite the beneﬁts seen with
control of these two risk factors, consider-
able residual risk remains. Identifying ad-
ditional risk factors for these common
complications could aid the tailoring of
risk assessment and development of novel
therapeutic strategies.
Reduced HDL cholesterol (HDL-C),
characteristic of type 2 diabetic dyslipidae-
mia (3), is a well-recognized risk factor for
macrovascular complications (4). We hy-
pothesized that lower HDL-C levels also
may predispose to the development and
progression of diabetic microvascular dis-
ease. In subjects without diabetes, low
HDL-C has been previously reported to be
an independent risk factor for the develop-
ment of chronic kidney disease (CKD)
(5–7), but there are limited prospective
data on the relationship between HDL-C
and the risk of diabetic nephropathy
(8–12). There are even fewer data on the
relationship between HDL-C levels and
retinopathy, with conﬂicting results in
nondiabetic patients (13–15), and no sig-
niﬁcant association found in those with
type 2 diabetes (16–20). Despite the pau-
city of epidemiological evidence, two large
randomized trials have recently reported
that fenoﬁbrate, an HDL-C–modifying
agent, reduces diabetes-related microvas-
cular disease (21–23).
The Action in Diabetes and Vascular
Disease: preterAx and diamicroN-MR
Controlled Evaluation (ADVANCE) Study
is the largest trial to date of glycemic control
and blood pressure lowering in patients
with type 2diabetes at high risk for vascular
events (24). The ADVANCE study enrolled
.11,000 patients with type 2 diabetes and
followed them systematically for the devel-
opment of microvascular complications. In
these analyses, we evaluate baseline HDL-C
level as a risk factor for the development of
new or worsening microvascular disease,
deﬁned as a composite of neworworsening
retinopathy and nephropathy.
RESEARCH DESIGN AND
METHODSdThe study design of the
ADVANCE study is reported in detail else-
where (24). In brief, 11,140 patients with
type 2 diabetes, aged at least 55 years at
study entry and with at least one other car-
diovascular risk factor, underwent factorial
randomization to 1) the ﬁxed combination
of perindopril and indapamide (4 mg/1.25
mg) or matching placebo and 2) intensive
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(gliclazide MR-based, to an HbA1c target of
#6.5%) or standard (usual care) glucose
control.Patientswere followed-up for ame-
dian of 5.0 years. The ADVANCE trial en-
rolled subjects from 20 countries in Asia,
Australasia, Europe, and North America. A
total of 11,126 patients with HDL-C mea-
surements at baseline were included in
these analyses. From this population,
1,602 patients were included in the AD-
VANCE Retinal Measurement (AdRem)
study, which involved serial retinal photog-
raphy (1,241 had assessable images). Study
design and themethods used in AdRem are
published in detail elsewhere (25). Ap-
proval for the study was obtained from
each center’s institutional ethics commit-
tee, and all participants provided written
informed consent.
Baseline and follow-up analysis
At baseline, venous blood was taken for a
fasting lipid proﬁle, HbA1c, and creatinine.
Blood pressure and BMI also were re-
corded. Creatinine was remeasured at 4
months and then annually. In addition,
urine samples were collected at baseline, 24
months, 48 months, and at the end of the
trial for determination of the urinary albu-
min-to-creatinine ratio (ACR). Fundoscopy
also was performed at these times. HDL-C
level was repeated at 24 and 48 months or
at the end of the study. All samples were
analyzed by local laboratories, and all as-
sessments could be repeated at physician
discretion. All nonstudy medication was
at the discretion of the local physician.
Participants in AdRem had retinal ste-
reoscopic photographs taken after the
ADVANCE trial randomization visit and
at the ﬁnal visit of the blood pressure arm
of the trial. All images were graded cen-
trally according to the Early Treatment of
Diabetic Retinopathy Study classiﬁcation
as modiﬁed in the UK Prospective Diabe-
tes Study (26).
Outcomes
The main outcomes for this analysis were
microvascularevents,deﬁnedasacomposite
of total renal and retinal events. Total renal
events were deﬁned as the development
of new microalbuminuria (urinary ACR
30–300 mg/mg), new macroalbuminuria
(urinary ACR of.300mg/mg), a doubling
of creatinine to at least 200 mmol/L, the
need for renal replacement therapy, or
death as a result of renal disease. Total ret-
inal events were deﬁned as the development
of proliferative retinopathy (new blood
vessels or ﬁbrous proliferations on the
disc or elsewhere, vitreous hemorrhage,
or preretinal hemorrhage), macular
edema, diabetes-related blindness, or the
use of retinal photocoagulation therapy.
Participants could record more than one
event relating to renal and retinal disease,
but only the ﬁrst event was analyzed for
total microvascular events.
Statistics
Differences in variables at baseline between
subgroups of the study population were
tested using the Student t test, the Mann-
Whitney test, or the x2 test, as appropriate.
Participants were censored at their date of
death or, for those still alive at the end of
follow-up, the date of their last visit. The
regression dilution bias in HDL-C was as-
sessed using a linear mixed model, with
HDL-C during follow-up as the outcome
and baseline HDL-C as the predictor. To
calculate the correction factor, HDL-C
measurements after microvascular events
were excluded (27). The risks of events as-
sociated with baseline HDL-C level were
estimated using Cox proportional hazards
models, with adjustment for potential con-
founding baseline covariates including age
(continuous), sex (male/female), ethnicity
(white/Asian/other), treatment groups
(standard vs. intensive glucose control and
placebo vs. ﬁxed-dose blood pressure–
lowering treatment), history of microvas-
cular disease (yes/no), smoking status
(current/previous/never), current alcohol
consumption (yes/no), HbA1c (continu-
ous), BMI (continuous), systolic bloodpres-
sure (continuous), diabetes duration
(continuous), total cholesterol (continu-
ous), creatinine (continuous), and statin
use (yes/no). The selection of variables
was based on identifying all measured clin-
ical variables of known or suspected prog-
nostic importance for the outcomes of
interest. The assumption of the propor-
tional hazards was checked graphically us-
ing the log cumulative hazard plot for all
variables included in the Cox model. The
primary analyses compared patients in the
highest with those in the lowest third (or
tertile group) of HDL-C. Additional sensi-
tivity analyses were performed comparing
the risks in those in the lowest with those in
the highest fourths (or quartile groups), ex-
cluding patients with microvascular dis-
ease, renal disease, or retinal disease at
baseline and examining subgroups deﬁned
by age, sex, ethnicity, systolic blood pres-
sure, BMI, and age. All P values were calcu-
lated from two-tailed tests of statistical
signiﬁcance with a type I error rate of 5%.
All analyses were performed using SAS ver-
sion 9.1 (SAS Institute, Cary, NC).
RESULTSdThe ADVANCE study en-
rolled patients with type 2 diabetes at
high risk for macrovascular events. At
baseline, 10% (n = 1,155) had evidence of
microvascular disease. During a median
follow-up period of 5 years, 32% (n =
3,585) of participants developed new or
worsening microvascular disease. Almost
one-third (n = 3,161 [28%]) developed a
renal event: microalbuminuria was the
most frequent event, followed by macro-
albuminuria, doubling of creatinine to at
least 200 mmol/L, renal-related death, and
the need for renal replacement therapy
(25, 3.4, 1.2, 0.3, and 0.2%, respectively).
A retinal event occurred in 6% (n = 680):
the need for laser therapy was the most
frequent event, followed by macular
edema, proliferative retinopathy, and
diabetes-related blindness (3.5, 3.2, 2.6,
and 0.4%, respectively).
Themean baselineHDL-C levelwas 1.3
mmol/L (SD 0.45mmol/L [range 0.1–4.0]).
Table 1 shows the distribution of variables
by thirds of baseline HDL-C level. Com-
paredwith the lowest third ofHDL-C, those
subjects in the highest third were less likely
to bemale (44.8 vs. 70.8%) or taking a stat-
in (24.9 vs. 31.1%) and more likely to have
lower BMI (27.7 vs. 29.1 kg/m2), lower se-
rum creatinine (82.5 vs. 91.0 mmol/L), and
to have never smoked (65.3 vs. 49.6%).
LowHDL-C alsowas associatedwith higher
triglycerides and lower total cholesterol and
LDL cholesterol. Age, diabetes duration,
systolic blood pressure, HbA1c, ethnicity,
and nonstatin lipid-lowering medication
use all were statistically signiﬁcantly differ-
ent between thirds; however, the absolute
differences were very small. The relative
differences between HDL groups and the
baseline variables of statin use, nonstatin
lipid-lowering medication use, systolic
blood pressure, and HbA1c remained stable
over the course of study follow-up (Supple-
mentary Table 1).
Table 2 shows the association, both
adjusted and unadjusted, between base-
line thirds of HDL-C and the risk of de-
veloping new or worseningmicrovascular
disease. Compared with the highest third
of HDL-C, those in the lowest third had
an 11% higher risk of a microvascular
event (unadjusted hazard ratio [HR]
1.11 [95% CI 1.02–1.20], P = 0.01). Fol-
lowing multivariable adjustment and tak-
ing into account regression dilution, the
risk was 17% higher (1.17 [1.06–1.28],
P = 0.001). This ﬁnding was driven by
an adjusted 19% higher risk of a renal
event (1.19 [1.08–1.32], P = 0.0005).
There was a similar signiﬁcantly higher
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risk of developing new microalbuminuria
andmacroalbuminuria (1.14 [1.03–1.27],
P = 0.01, and 1.42 [1.07–1.87], P = 0.01,
respectively). Furthermore, we observed
that those patients in the lowest third of
HDL-C were more likely to maintain or
progress to a worse category of urinary
ACR over time, compared with those in
the middle and highest third of HDL-C
(66.8 vs. 62.0 and 58.8%, respectively)
(Supplementary Table 2).
The direction of the effect was similar,
however not statistically signiﬁcant follow-
ing adjustment, to the other renal out-
comes of doubling of creatinine to at least
200 mmol/L and renal-related death. In
contrast to the other renal outcomes, the
association with the need for renal
replacement therapy (the end point with
the smallest number of events) was non-
linear.
There was no association between
baseline thirds of HDL-C and the develop-
ment of retinopathy or any speciﬁc type of
retinal event. Furthermore, there was no
association between baseline HDL-C and a
wide range of predeﬁned retinal outcomes
Table 1dBaseline variables of study subjects by thirds of serum HDL-C
HDL thirds
P for
trend
Third 1
(,1.1 mmol/L)
Third 2
(1.1–1.34 mmol/L)
Third 3
(.1.34 mmol/L)
n 3,497 3,924 3,705
Age at baseline (years) 65.2 (6.4) 65.9 (6.5) 66.1 (6.3) ,0.0001
Male (%) 70.8 (2,475) 57.7 (2,264) 44.8 (1,661) ,0.0001
Diabetes duration (years) 7.7 (6.3) 8.0 (6.4) 8.2 (6.4) 0.001
BMI (kg/m2) 29.1 (5.3) 28.3 (5.0) 27.7 (5.2) ,0.0001
Systolic blood pressure (mmHg) 144.3 (21.0) 144.9 (21.6) 145.8 (21.9) 0.003
HbA1c (%) 7.6 (1.5) 7.5 (1.6) 7.5 (1.6) 0.01
Serum creatinine (mmol/L) 91.0 (26.9) 86.4 (23.5) 82.5 (25.1) ,0.0001
ACR (mg/mg) 54.9 (119.5) 51.5 (111.8) 51.4 (114.4) 0.2
Total cholesterol (mmol/L) 4.8 (1.2) 5.2 (1.1) 5.6 (1.2) ,0.0001
LDL (mmol/L) 2.9 (0.9) 3.1 (1.0) 3.2 (1.0) ,0.0001
HDL (mmol/L) 0.91 (0.12) 1.20 (0.08) 1.64 (0.29)
Triglycerides (mmol/L) 2.3 (1.5) 1.9 (1.2) 1.7 (1.2) ,0.0001
Smoking status (%)
Never 49.6 (1,734) 56.9 (2,232) 65.3 (2,418) ,0.0001
Former 32.9 (1,151) 27.5 (1,081) 22.4 (830)
Current 17.5 (612) 15.6 (611) 12.3 (457)
Current alcohol intake (%)
No 68.4 (2,391) 69.9 (2,744) 70.2 (2,600) 0.2
Yes 31.6 (1,106) 30.1 (1,180) 29.8 (1,105)
Ethnicity (%)
White/European 64.7 (2,261) 59.8 (2,348) 55.8 (2,066) ,0.0001
Asian 33.1 (1,159) 38.5 (1,510) 42.3 (1,569)
Other 2.2 (77) 1.7 (66) 1.9 (70)
Statin use (%)
No 68.9 (2,410) 71.1 (2,789) 75.1 (2,784) ,0.0001
Yes 31.1 (1,087) 28.9 (1,135) 24.9 (921)
Nonstatin lipid-lowering
medication (%)
No 90.2 (3,156) 92.3 (3,620) 92.2 (3,416) 0.002
Yes 9.8 (341) 7.7 (304) 7.8 (289)
History of microvascular
disease (%)
No 89.8 (3,140) 90.1 (3,537) 88.9 (3,294) 0.2
Yes 10.2 (357) 9.9 (387) 11.1 (411)
Randomized glucose
treatment (%)
Standard 49.6 (1,736) 50.3 (1,972) 50.0 (1,853) 0.9
Intensive 50.4 (1,761) 49.7 (1,952) 50.0 (1,852)
Randomized blood pressure
treatment (%)
Placebo 49.4 (1,728) 49.6 (1,947) 51.0 (1,891) 0.3
Perindopril-indapamide 50.6 (1,769) 50.4 (1,977) 49.0 (1,814)
Data are means (SD) or % (n). Bold values are statistically signiﬁcant values (P# 0.05). P values refer to the Student t test, the Mann-Whitney test, or the x2 test, as
appropriate.
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from the AdRem substudy involving 1,241
participants who underwent assessable se-
rial retinal photography, which included
progression by the Early Treatment of
Diabetic Retinopathy Study classiﬁcation
and the development of the individual
signs of retinopathy (data not shown).
Sensitivity analyses by fourths (or
quartile groups) of HDL-C revealed similar
ﬁndings, namely an inverse relationship
between HDL-C level and total microvas-
cular events that was driven primarily by
renal events, with no relationship found
between HDL-C and retinal events. Sensi-
tivity analyses excluding patients with
baseline microvascular disease also were
similar to the main analysis. When strati-
ﬁed by subgroups deﬁned by age, sex,
ethnicity, systolic blood pressure, BMI, or
HbA1c, there was no evidence of heteroge-
neity in the association.
CONCLUSIONSdThis study is the
largest prospective analysis speciﬁcally ad-
dressing HDL-C level and risk of micro-
vascular disease in patients with type 2
diabetes. The main ﬁnding is that lower
baseline HDL-C level is a signiﬁcant and
independent predictor of the develop-
ment and progression of diabetic ne-
phropathy. Compared with patients in
the highest third, those in the lowest third
of baseline HDL-C had a 19% higher risk
of nephropathy, after adjustment for a
wide range of potential confounders and
accounting for regression dilution. In
contrast, there was no association between
baseline HDL-C and the risk of diabetic
retinopathy. These ﬁndings suggest that
differences exist in the pathophysiology
between the two types of microvascular
disease.
Our ﬁndings provide the strongest
evidence to date for a role of HDL-C in
the development and progression of di-
abetic nephropathy in patients with type 2
diabetes. Several small prospective studies
have shown that low HDL-C predicts pro-
gression of microalbuminuria (8–10);
however, others have not identiﬁed such
an association (28,29). The largest previous
study evaluating this question included
2,193 patients with type 2 diabetes and
normal renal function at baseline. In this
study, each 0.26 mmol/L higher level of
HDL was associated with a 24% lower
risk of developing stage 3 chronic kidney
disease (11). This was not a prespeciﬁed
end point of the ADVANCE study; how-
ever, we are the ﬁrst to show an inverse
relationship between baseline HDL-C and
total renal microvascular events.T
ab
le
2d
A
ss
oc
ia
ti
on
be
tw
ee
n
ba
se
lin
e
th
ir
ds
of
H
D
L
-C
(t
er
ti
le
[T
]
1,
T
2,
an
d
T
3)
an
d
su
bs
eq
ue
nt
de
ve
lo
pm
en
t
of
m
ic
ro
va
sc
ul
ar
di
se
as
e
U
na
d
ju
st
ed
M
ul
tiv
ar
ia
bl
e
ad
ju
st
ed
*
T
1
vs
.T
3‡
P
T
2
vs
.T
3‡
P
T
3
P
T
1
vs
.T
3‡
P
T
2
vs
.T
3‡
P
T
3
P
T
ot
al
m
ic
ro
va
sc
u
la
r
ev
en
ts
1.
11
(1
.0
2–
1.
20
)
0.
0
1
1.
09
(1
.0
0–
1.
18
)
0.
0
4
1
d
1.
17
(1
.0
6–
1.
28
)
0.
00
1
1.
11
(1
.0
2–
1.
20
)
0.
0
2
1
d
T
ot
al
ki
dn
ey
ev
en
ts
1.
15
(1
.0
6–
1.
26
)
0.
0
01
1.
13
(1
.0
4–
1.
23
)
0.
0
06
1
d
1.
19
(1
.0
8–
1.
32
)
0.
00
05
1.
13
(1
.0
4–
1.
24
)
0.
0
06
1
d
N
ew
m
ic
ro
al
bu
m
in
ur
ia
1.
08
(0
.9
8–
1.
18
)
0.
1
1.
09
(1
.0
0–
1.
20
)
0.
0
5
1
d
1.
14
(1
.0
3–
1.
27
)
0.
01
1.
10
(1
.0
1–
1.
21
)
0.
0
4
1
d
N
ew
m
ac
ro
al
bu
m
in
ur
ia
1.
53
(1
.1
9–
1.
97
)
0.
0
01
1.
25
(0
.9
7–
1.
62
)
0.
07
1
d
1.
42
(1
.0
7–
1.
87
)
0.
01
1.
20
(0
.9
2–
0.
15
7)
0.
2
1
d
D
ou
bl
in
g
of
cr
ea
ti
ni
n
e
to
$
20
0
m
m
ol
/L
1.
71
(1
.1
0–
2.
66
)
0.
0
2
1.
33
(0
.8
4–
2.
09
)
0.
2
1
d
1.
44
(0
.8
9–
2.
35
)
0.
1
1.
31
(0
.8
2–
2.
10
)
0.
3
1
d
N
ee
d
fo
r
re
n
al
re
pl
ac
em
en
t
th
er
ap
y
0.
80
(0
.2
8–
2.
31
)
0.
7
1.
54
(0
.6
4 –
3.
70
)
0.
3
1
d
0.
74
(0
.2
4–
2.
31
)
0.
6
1.
80
(0
.7
1–
4.
59
)
0.
2
1
d
R
en
al
-r
el
at
ed
de
at
h
1.
24
(0
.5
6–
2.
78
)
0.
6
1.
12
(0
.5
0–
2.
50
)
0.
8
1
d
1.
16
(0
.4
7–
2.
89
)
0.
7
1.
29
(0
.5
5–
2.
99
)
0.
6
1
d
T
ot
al
re
tin
al
ev
en
ts
0.
90
(0
.7
4–
1.
08
)
0.
3
0.
93
(0
.7
8–
1.
11
)
0.
4
1
d
1.
01
(0
.8
2–
1.
25
)
0.
9
0.
98
(0
.8
2–
1.
18
)
0.
9
1
d
N
ew
pr
ol
ife
ra
ti
ve
re
tin
op
at
hy
0.
76
(0
.5
7–
1.
02
)
0.
07
0.
85
(0
.6
4–
1.
11
)
0.
2
1
d
0.
92
(0
.6
7–
1.
26
)
0.
6
0.
93
(0
.7
1–
1.
24
)
0.
6
1
d
M
ac
ul
ar
ed
em
a
1.
02
(0
.7
9–
1.
33
)
0.
9
1.
04
(0
.8
1–
1.
34
)
0.
8
1
d
1.
18
(0
.8
8–
1.
58
)
0.
3
1.
12
(0
.8
6–
1.
46
)
0.
4
1
d
D
ia
be
te
s-
re
la
te
d
bl
in
d
ne
ss
0.
71
(0
.3
2–
1.
59
)
0.
4
1.
19
(0
.6
1–
2.
35
)
0.
6
1
d
1.
03
(0
.4
4–
2.
41
)
0.
9
1.
51
(0
.7
5–
3.
03
)
0.
2
1
d
N
ee
d
fo
r
la
se
r
th
er
ap
y
1.
07
(0
.8
4–
1.
38
)
0.
6
1.
09
(0
.8
5–
1.
39
)
0.
5
1
d
1.
18
(0
.8
9–
1.
55
)
0.
2
1.
14
(0
.8
9–
1.
47
)
0.
3
1
d
Bo
ld
va
lu
es
ar
e
st
at
is
ti
ca
lly
si
gn
iﬁ
ca
n
tv
al
u
es
(P
#
0.
05
).
*A
d
ju
st
ed
fo
r
re
gr
es
si
on
di
lu
ti
on
an
d
ba
se
lin
e
ag
e,
se
x,
et
h
ni
ci
ty
,t
re
at
m
en
tg
ro
u
ps
,h
is
to
ry
of
m
ic
ro
va
sc
ul
ar
di
se
as
e,
sm
ok
in
g
st
at
us
,c
ur
re
nt
dr
in
ki
ng
,H
bA
1
c,
BM
I,
sy
st
ol
ic
bl
oo
d
pr
es
su
re
,d
ia
be
te
s
du
ra
tio
n
,s
ta
tin
us
e,
an
d
ba
se
lin
e
cr
ea
ti
ni
ne
,t
ot
al
ch
ol
es
te
ro
l,
an
d
tr
ig
ly
ce
ri
de
le
ve
ls
.‡
C
ox
pr
op
or
ti
on
al
H
R
(9
5%
C
I)
,h
ig
he
st
th
ir
d
as
re
fe
re
nc
e.
2204 DIABETES CARE, VOLUME 35, NOVEMBER 2012 care.diabetesjournals.org
HDL and risk of microvascular disease
We observed no signiﬁcant association
between HDL-C and a whole spectrum of
retinal complications. Although some non-
HDL lipid fractions previously have been
reported to be associated with the severity
and progression of retinopathy in patients
with type 2 diabetes, no study has shown
an association with HDL-C (16,20), and
our study is concordantwith this literature.
Our ﬁndings may be explained by the na-
ture of the retinal events examined as the
most frequent retinal end point was laser
photocoagulation. Because this procedural
event is likely to be driven by health service
availability and local usual practice in addi-
tion to biological risk in a multicenter, in-
ternational study such as this, its inclusion
may have diluted any causal link, if any
such association existed. However, we
also found no evidence of an association
with any of the speciﬁc end points exam-
ined in the small proportion of ADVANCE
trial participants who underwent serial ret-
inal photography, a more sensitive and ob-
jective measure of retinal disease.
The Fenoﬁbrate Intervention in End
Point Lowering in Diabetes Trial showed
that fenoﬁbrate reduced the development
of renal dysfunction and the need for
retinal laser therapy (22,30). In support of
our ﬁndings of an association between
HDL-C and renal events but not retinal
events, fenoﬁbrate seemed to be more pro-
tective against the estimated glomerular ﬁl-
tration rate loss in those with baseline
dyslipidemia (deﬁned as low HDL-C and
high triglycerides) (30), whereas the retinal
beneﬁt was independent of any lipid frac-
tion (22). In much the same way, the more
recent Action to Control Cardiovascular
Risk inDiabetes eye study showed a beneﬁt
of fenoﬁbrate added to statin therapy on
the progression of diabetic retinopathy,
without an appreciable change in HDL-C
level (HDL-C at 1 year 1.03 mmol/L in the
fenoﬁbrate group compared with 1.01
mmol/L in the placebo group) (23). The
salient conclusion from these two studies
of fenoﬁbrate therapy is that treatment re-
duced bothmicrovascular complications in
type 2 diabetes. This effect, at least in part,
may be related to HDL-C level for renal but
not retinal complications. On the horizon,
there is the promising cholesterylester
transfer protein inhibitor, anacetrapib,
which increases HDL-C by 138% (31).
Our ﬁndings suggest that investigating
the effect of HDL-C–modulating agents
on the development of diabetic nephropa-
thy is warranted.
The pathogenesis of diabetic microvas-
cular disease is complex and involves the
interplay of endothelial dysfunction, ad-
vanced end-glycation products, oxidative
stress, and the abnormal production of
cytokines and growth factors (32,33). The
pathobiology of diabetic nephropathy
and retinopathy is heterogeneous, with
no single characteristic lesion (33,34). Al-
though retinopathy and nephropathy can
coexist in the same patient, the association
is less clear in type 2 rather than type 1
diabetes (35), perhaps an indication of dif-
fering pathophysiology. HDL-C itself is a
complex of several lipoproteins, choles-
terol, and triglycerides and has several
postulatedmechanisms of vascular action,
notably reverse cholesterol transport as
well as anti-inﬂammatory and antioxidant
properties (36). Furthermore, there is
emerging evidence that HDL-C improves
glycemic control by modulating glucose
uptake into skeletal muscle (37) and pro-
tects against islet b-cell dysfunction (38).
Although the exact putative mechanism
for protection is unknown, it is clear that
HDL-C exerts beneﬁcial effects onmany of
the pathways known to be detrimental to
vascular and kidney biology, but how
this could be different in retinopathy is
unclear.
Following the development of micro-
albuminuria, 20–40% of patients with type
2 diabetes will progress to overt nephrop-
athy (1). Many randomized trials have
shown a clear beneﬁt for the treatment of
this asymptomatic condition; thus, early
detection is critical (39). International
guidelines recommend screening at the
time of diagnosis of diabetes and thereaf-
ter annually for patients with normoalbu-
minuria (1). The optimum timing of
creatinine clearance measurement is un-
known. The use of HDL-C level, along
with other established risk factors, may
help identify patients at high risk of devel-
opment and progression of nephropathy
and therefore warrant more frequent
testing.
The strengths of this study are its
large sample size, with an ethnically di-
verse population and rigorous collection
of data. This allowed precise estimation of
the independent effect of HDL-C on the
development and progression of prede-
ﬁned diabetic microvascular disease out-
comes. Our study also has a number of
limitations. Because it is a post hoc ob-
servational analysis of data from a ran-
domized controlled trial, the results
should be interpreted as hypothesis gen-
erating. Despite the size of this study,
there were very few events for some of the
end points such as the need for renal
replacement therapy and renal death,
which limited our ability to provide ac-
curate estimates of the associations for
these outcomes. Although the difference
was small (,2.7%), adherence to the
study ACE inhibitor (perindopril) was
slightly lower in the lowest HDL-C third
compared with the middle and highest
third (77.1, 79.2, and 79.8%, respec-
tively). We cannot exclude that this may
have had an effect on renal outcomes. In
addition, it is possible that not all sub-
types of HDL-C have the same relation-
ship with microvascular outcomes.
However, we were unable to measure sub-
type and function of HDL-C in order to
explore these relationships in our study.
In conclusion, in a large population of
patients with type 2 diabetes and after
adjustment for a wide variety of confound-
ers, low HDL-C level was shown to be an
independent risk factor for the develop-
ment and progression of diabetic nephrop-
athy. Measurement of this lipid fraction
may be useful in tailoring screening and
therapeutic strategies. Additional research
is needed to explore the possible beneﬁts of
therapies that increase HDL-C in patients
with type 2 diabetes.
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